A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Copanlisib (Primary) ; Niraparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 09 Aug 2019 Planned End Date changed from 30 Apr 2022 to 1 Apr 2022.
- 10 Jun 2019 Planned End Date changed from 1 Apr 2022 to 30 Apr 2022.
- 10 Jun 2019 Planned primary completion date changed from 1 Apr 2021 to 30 Apr 2021.